Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers


WELLESLEY, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proceeds will be used to discover and develop novel therapeutics directed toward differentiation therapy, which reactivates endogenous cellular programs to elicit tumor cell maturation and differentiation.

Visit link:
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers

Related Posts